Biopharmaceutical firm Berg and the Icahn School of Medicine at Mount Sinai have entered into a pharmaceutical and diagnostic R&D deal to leverage the power of multi-omic biology and data analytics.
The deal is intended to secure new insights and potential therapeutics for cancer, central nervous system and endocrine disorders.
Under the five-year deal, Berg will use its Interrogative Biology platform in combination with Mount Sinai's expertise in big data, advanced analytics and biological network modeling.
Both the parties will adopt a new risk and return sharing approach, with downstream royalties higher compared to the industry standard for academia-pharma partnerships.
Berg co-founder, president and CTO Niven Narain said the partnership with Mount Sinai flips the traditional public-private partnership model and sets a new standard for pharmaceutical research and development.
"Innovation in the healthcare industry extends far beyond scientific and technological advances. In order to address some of the world's worst health crises, we need to be open to such new and innovative ways of working together," Narain added.
The deal will also see both the parties engage in research projects involving the fields of genomics, proteomics, lipidomics, metabolomics and functional phenotypes.
The partnership is aimed at advancing treatment options for cancer, CNS and endocrine disorders, as well as inflammation and obesity, and infectious and rare disease patients.
